For a dog owner, few words from a veterinarian are as devastating as a diagnosis of oral melanoma. Canine oral melanoma is an aggressive, fast-growing cancer with a high propensity to metastasize (spread) to the local lymph nodes and lungs. Historically, local control—consisting of aggressive surgery and often radiation therapy—was the only weapon available, and even after successful removal, the median survival time for advanced stages remained discouragingly short.

In 2007, a new therapeutic option entered the veterinary oncology space: the Oncept Canine Melanoma Vaccine (manufactured by Merial, which was acquired by Boehringer Ingelheim Animal Health in 2017). It was hailed as a breakthrough—the first USDA-licensed therapeutic DNA vaccine for cancer in any species.

However, if you search for Oncept online, you will quickly encounter a landscape of conflicting opinions. On one side, manufacturer materials, clinic websites, and some veterinary oncologists strongly advocate for the vaccine as a life-extending treatment. On the other side, several retrospective peer-reviewed clinical studies have raised questions about its efficacy, finding no statistically significant difference in survival times between vaccinated and unvaccinated dogs.

This clinical monograph examines the Oncept vaccine in detail. We outline the science of how it works, detail the ACVIM specialist restrictions and current pricing, explore the regulatory differences between USDA licensing and FDA approval, analyze the pivotal clinical trials alongside later retrospective studies, and discuss the position of the 2026 AAHA Oncology Guidelines to help pet owners and veterinary teams make an informed decision.

---

The short answer, first

Oncept is a USDA-licensed, therapeutic DNA vaccine designed to treat Stage II or III canine oral melanoma after local surgical removal or radiation control. Rather than preventing cancer, it works immunotherapeutically by training the dog's immune system to attack melanoma cells.

The primary controversy surrounding Oncept centers on evidentiary standards. Because it is classified as a veterinary biologic, Oncept was licensed by the USDA Center for Veterinary Biologics (CVB) rather than approved by the FDA Center for Veterinary Medicine (CVM). USDA approval requires showing safety and a "reasonable expectation of efficacy," which is a lower barrier than the randomized, double-blind, placebo-controlled trials required by the FDA.

Subsequent retrospective studies (such as the Verganti 2017 UK study) have yielded mixed results, showing no definitive survival advantage for some cohorts. The vaccine is restricted to boarded oncology and internal medicine specialists, and a typical four-dose initial series costs between $3,200 and $5,600 ($800 to $1,400 per dose), excluding clinic fees and staging diagnostics.

For context on general cancer treatment costs, see our overview on the cost of dog cancer treatment. To understand the diagnostic and staging workup for canine cancers, read our guide on canine lymphoma diagnosis, staging, and treatment. For regulatory details on USDA veterinary biologics, read our guide on how USDA licenses veterinary biologics.

---

Understanding canine oral melanoma

Before evaluating the vaccine, we must understand the disease it is designed to target. Oral melanoma is the most common malignant oral tumor in dogs, accounting for roughly 30% to 40% of all oral malignancies. It is highly invasive locally, frequently invading the underlying jawbone, and is characterized by early metastasis.

The staging system

Canine oral melanoma is staged according to the World Health Organization (WHO) system, which is based on tumor size and metastasis:

• Stage I: Tumor is less than 2 cm in diameter; no lymph node or distant metastasis.
• Stage II: Tumor is 2 cm to less than 4 cm in diameter; no lymph node or distant metastasis.
• Stage III: Tumor is 4 cm or larger, or any tumor size with local lymph node metastasis.
• Stage IV: Any tumor size with distant metastasis (typically to the lungs or liver).

Local control is mandatory

It is critical to understand that Oncept is not a standalone treatment. The vaccine is labeled to "aid in extending survival of dogs with Stage II or III oral melanoma for which local disease control has been achieved."

Local control means removing the primary tumor via aggressive surgery (such as a mandibulectomy or maxillectomy) or local radiation therapy to clear the margins. If the primary tumor is left intact, the vaccine cannot overcome the massive local tumor burden. It is designed to target the microscopic, residual metastatic cells that have already broken away and are circulating in the body or resting in distant organs.

---

How the Oncept vaccine works: Xenogeneic DNA immunotherapy

Most traditional vaccines work by injecting a weakened pathogen or a protein subunit to train the immune system against an external threat, like a virus. Oncept is different: it is a therapeutic DNA vaccine given to a patient who already has cancer, designed to target the patient's own cells.

The biological target: Tyrosinase

Melanoma cells, which are derived from pigment-producing melanocytes, overexpress an enzyme called tyrosinase. Tyrosinase is essential for melanin (pigment) synthesis. Because tyrosinase is highly concentrated in melanoma cells compared to normal body cells, it represents an ideal target for immunotherapy.

However, a dog's immune system does not naturally attack its own tyrosinase because it recognizes the protein as "self"—a phenomenon known as immune tolerance.

The xenogeneic solution: Human DNA

To break this tolerance, Oncept utilizes xenogeneic (foreign-sourced) DNA. The vaccine consists of a plasmid (a small ring of DNA) that contains the gene encoding human tyrosinase (USDA Product Code 9240.D0).

When the human DNA plasmid is injected into the dog:

1. The dog's muscle and skin cells take up the plasmid and begin producing the human tyrosinase protein.
2. Because human tyrosinase is foreign to the dog's immune system, it triggers an immune response.
3. Crucially, human tyrosinase is structurally similar to canine tyrosinase. The antibodies and T-cells generated against the human protein cross-react with the dog's own canine tyrosinase.
4. The dog's immune system now identifies the dog's melanoma cells as targets and begins attacking them.

The Vet Jet transdermal device

Oncept is not injected with a standard syringe. It is administered using the Vet Jet transdermal vaccination system—a needle-free injection device that uses high pressure to deliver the plasmid DNA vaccine through the skin and into the medial thigh region. This needle-free delivery is important because it disperses the DNA plasmids across a wider surface area of immune-rich tissue than a standard needle, facilitating cellular uptake and antigen presentation.

---

The regulatory landscape: USDA licensing vs. FDA approval

To understand the controversy surrounding Oncept's efficacy, one must understand the regulatory pathway through which it was approved.

USDA Center for Veterinary Biologics (CVB)

In the United States, animal health products are regulated by different agencies based on their mechanism of action:

• The FDA Center for Veterinary Medicine (CVM) regulates chemical drugs (like antibiotics, NSAIDs, and chemotherapeutics).
• The USDA Center for Veterinary Biologics (CVB) regulates veterinary biologics, which include vaccines, bacterins, diagnostics, and immunotherapies.

Because Oncept works by stimulating an immune response (an immunotherapy/vaccine), it fell under the jurisdiction of the USDA, not the FDA.

The evidentiary standards

The standards for approval differ significantly between the two agencies:

• FDA CVM Pathway: Requires proof of safety and substantial evidence of efficacy through prospective, randomized, double-blinded, placebo-controlled clinical trials. The FDA requires the drug manufacturer to prove that the drug works better than a placebo in a statistically significant manner.
• USDA CVB Pathway: Requires proof of safety and a "reasonable expectation of efficacy." For vaccines and biologics, the USDA historically allowed products to obtain conditional licensure and eventually full licensure with studies using historical controls (comparing vaccinated dogs to a historical database of unvaccinated dogs), rather than requiring active, prospective placebo-controlled groups.

Oncept was granted conditional licensure by the USDA in 2007 and achieved full licensure in 2010. Critics argue that because it was never subjected to the rigorous, prospective, double-blinded placebo-controlled trials required by the FDA, the initial claims regarding its survival benefit were over-extrapolated.

---

Clinical evidence: The pivotal trial vs. subsequent studies

To evaluate whether Oncept actually works, we must compare the initial data that led to its licensure with subsequent independent, retrospective clinical studies.

1. The pivotal licensing trial (Grosenbaugh et al., 2011)

The USDA licensing study evaluated 58 dogs with Stage II or III oral melanoma that had achieved local control via surgery and, where margins were incomplete, radiation therapy. Because there was no active control group, the researchers compared the vaccinated dogs to a historical database of 53 dogs treated at a single academic institution that had achieved local disease control.

The results:

• Historical Controls: The median survival time (MST) for the historical control group was 324 days (roughly 10.8 months).
• Vaccinated Group: The MST for the vaccinated group was not reached during the study period, because fewer than 50% of the vaccinated dogs had died of oral melanoma at the final survival follow-up.
• Interpretation: Based on this comparison, the USDA concluded that there was a "reasonable expectation of efficacy," and the product was fully licensed in 2010.

2. Real-world single-arm data (Verganti et al., 2017, Journal of Small Animal Practice)

As Oncept became widely used, independent academic oncologists began tracking its real-world performance. Verganti and colleagues retrospectively evaluated 69 dogs with oral malignant melanoma across five UK institutions.

The results:

• Survival statistics: For dogs with stage I–III disease, the MST was 455 days (median disease-free interval of 222 days).
• Key limitation: This was a single-arm study with no concurrent unvaccinated control group, so on its own it cannot prove whether Oncept added survival benefit beyond surgery and radiation. It essentially confirmed that real-world UK outcomes fell in a similar range to the licensing data, without ruling benefit in or out.

3. Controlled comparisons finding no survival benefit (Ottnod et al., 2013)

The most direct challenge to the vaccine's benefit comes from controlled retrospective studies that compared vaccinated and unvaccinated dogs side by side. Ottnod and colleagues (2013, Veterinary and Comparative Oncology) evaluated 45 dogs with locoregionally controlled oral melanoma — 22 received Oncept and 23 did not.

The results:

• No significant difference: There was no statistically significant difference between vaccinated and unvaccinated dogs in progression-free survival (199 vs 247 days), disease-free interval (171 vs 258 days), or MST (485 vs 585 days).
• Interpretation: If anything, the unvaccinated group trended toward longer survival. This matched-control design is exactly the type of head-to-head comparison the pivotal licensing trial lacked, and it is why the survival benefit remains genuinely debated.

4. Systematic literature reviews (e.g., PMC9693055, 2022)

A comprehensive literature review published in PMC/NIH in 2022 analyzed all published clinical studies on the Oncept vaccine from 2007 to 2021.

The review highlighted why clinical results conflict:

• Study Designs: Most studies showing a positive effect for Oncept were retrospective and used historical controls, which are prone to selection bias (owners who choose and can afford the vaccine may also seek other supportive care or have dogs with less advanced sub-stages).
• Mixed Outcomes: Several subsequent multi-institutional retrospective studies failed to replicate the dramatic survival curves of the original licensing trials, showing either marginal or no survival benefits in randomized or matched cohorts.
• Summary Position: The review concluded that while Oncept is remarkably safe, its therapeutic efficacy remains controversial and is highly dependent on patient selection, tumor sub-stage, and the completeness of local control.

Table 1: Comparison of clinical studies on the Oncept Canine Melanoma Vaccine

Study / Source	Cohort Size (N)	Control Group Type	Key Finding	Reported Median Survival Time (MST)
Pivotal trial (Grosenbaugh et al., 2011)	58 vaccinated vs 53 controls	Historical	Survival benefit; MST not reached vs 324 days.	Vaccinated: Not Reached / Controls: 324 Days
Verganti et al. (JSAP, 2017)	69	None (single-arm)	Real-world MST in a similar range; cannot prove added benefit.	Stage I–III: 455 Days
Ottnod et al. (Vet Comp Oncol, 2013)	45 (22 vaccinated vs 23 unvaccinated)	Concurrent (matched)	No statistically significant survival benefit.	Vaccinated: 485 Days / Unvaccinated: 585 Days

---

2026 AAHA Oncology Guidelines and current specialist views

The veterinary oncology community is divided on how to approach the Oncept vaccine. This division is reflected in the official guidelines of our major professional organizations.

The 2026 AAHA Oncology Guidelines

The American Animal Hospital Association (AAHA) 2026 Oncology Guidelines for Dogs and Cats address therapeutic cancer immunotherapies under the "Therapeutic Interventions" section.

The guidelines state:

• Immunotherapy represents a highly promising future modality, but progress in canine solid tumors has been mixed.
• For the canine melanoma vaccine, the guidelines acknowledge the conflicting literature, noting that while the safety profile is excellent, the clinical data regarding its survival benefit are not uniform.
• AAHA advises clinicians to discuss the vaccine as an optional adjunct therapy rather than an absolute requirement, ensuring that owners understand the mixed evidence base before committing financially.

The specialist restriction

Oncept is not available to general-practice veterinarians. According to the Boehringer Ingelheim Oncept Order Form, purchase of the vaccine is restricted to:

1. ACVIM Diplomates (board-certified veterinary oncologists or internal medicine specialists).
2. ACVR Diplomates (board-certified veterinary radiation oncologists).

This restriction is in place because local control (surgery/radiation) and precise clinical staging are prerequisites for the vaccine to have any clinical utility. A general practitioner must refer the patient to a boarded specialist for the vaccine to be prescribed and administered.

For guidelines on when to refer a oncology patient to a specialist, read our practice manual on when to refer a cancer case.

---

The Oncept dosing schedule and administration protocol

If you and your veterinary oncologist decide to proceed with Oncept, the administration follows a specific protocol:

Table 2: The standard Oncept vaccination protocol

Phase	Dosing Interval	Number of Doses	Administration Method	Purpose
Initial Series	Every 2 weeks	4 doses total	Vet Jet transdermal device (medial thigh)	To break immune tolerance and prime the anti-tyrosinase response.
Maintenance / Booster	Every 6 months	Ongoing (lifetime)	Vet Jet transdermal device	To maintain antibody and T-cell populations over time.

Administration details

The Vet Jet device is pressed firmly against the medial thigh. When triggered, a loud "pop" sound is heard as the vaccine is delivered transdermally. The administration does not require sedation, and most dogs tolerate the brief pressure and sound well, though some may startle.

---

Side effects and safety profile: What the data shows

While Oncept's efficacy is debated, its safety profile is widely agreed to be excellent. In clinical trials and post-marketing surveillance, adverse events have been minor and transient.

Labeled side effects

The manufacturer's label lists the following potential adverse reactions:

• Mild injection site reactions: A small, firm swelling (nodule) may develop at the injection site. This is a normal immune response to the plasmid DNA and typically resolves without treatment within a few weeks.
• Transient pain or bruising: Minor bruising or localized discomfort immediately after Vet Jet discharge.
• Mild systemic signs: Mild lethargy or a low-grade fever for 24 to 48 hours after vaccination.

Passive surveillance reports

Adverse-event reports submitted to the USDA and CFIA reflect these localized patterns. There are no reports of severe autoimmune disease (such as systemic vitiligo, which in theory could occur if the immune system began aggressively attacking all normal pigment-producing melanocytes in the body), and the overall incidence of serious adverse events remains extremely low.

---

Cost analysis: Is it worth it?

The financial commitment is a major consideration for owners deciding whether to pursue Oncept. Because the vaccine is proprietary and restricted to specialist clinics, costs are high.

The cost breakdown:

The figures below are owner- and clinic-reported estimates, not an official manufacturer list price. Oncept is sold only through specialty clinics, so pricing varies by region, institution, and whether staging or administration is bundled into the per-dose fee.

• Per-Dose Cost: The cost of the vaccine itself, plus specialist administration and a brief exam, typically ranges from $800 to $1,400 per dose.
• Initial Series Cost: The initial four-dose series (administered over 6 weeks) costs between $3,200 and $5,600.
• Annual Maintenance Cost: The two semi-annual booster doses cost between $1,600 and $2,800 per year.
• Exclusions: These figures do not include the cost of the initial staging diagnostics (blood work, chest X-rays, abdominal ultrasound, lymph node aspirates), the surgery or radiation required for local control, or subsequent oncology recheck visits.

How to decide

Given the mixed evidence of survival benefit, how should a pet owner weigh this cost?

• If budget is not a constraint: Oncept represents a highly safe, low-risk adjunct therapy that may extend survival with virtually no side effects, making it a reasonable choice for owners who want to pursue every available option.
• If budget is a constraint: It is critical to prioritize funds for complete local control (aggressive surgery or radiation) and proper staging first. Committing to the vaccine at the expense of a margins-clear surgery or necessary pain management is clinically counterproductive, as the vaccine will fail if local disease control is incomplete.

---

FAQs

Is Oncept a cure for canine melanoma?

No. Oncept is not a cure. It is a therapeutic vaccine designed to slow the progression of metastatic disease and extend survival. Melanoma remains a terminal diagnosis for most dogs, and the goal of Oncept is to extend the quantity and maintain the quality of the dog's remaining life.

Why is Oncept USDA-licensed but not FDA-approved?

Oncept is classified as a veterinary biologic because it works by stimulating the dog's immune system. Under US law, veterinary biologics are regulated by the USDA, which requires showing safety and a "reasonable expectation of efficacy," rather than the FDA, which requires prospective, placebo-controlled trials.

Can Oncept be used for melanomas outside the mouth?

While Oncept is USDA-labeled specifically for oral melanoma, veterinary oncologists frequently use it "extralabel" (off-label) for melanomas arising in other locations, such as the nail bed (ungual melanoma) or the skin (cutaneous melanoma). The biological target (tyrosinase) is the same, and retrospective studies on digit melanomas suggest a similar safety and variable efficacy profile.

How many doses of Oncept does a dog need?

A dog requires an initial series of 4 doses given every 2 weeks, followed by a booster dose every 6 months for the rest of their life to maintain the immune response.

---

Sources

1. AAHA Oncology Guidelines (2026): 2026 AAHA Oncology Guidelines for Dogs and Cats, Section 5: Therapeutic Modalities - Immunotherapy.
2. Boehringer Ingelheim Product Page: ONCEPT Canine Melanoma Vaccine, DNA.
3. PMC Literature Review: The Use of Oncept Melanoma Vaccine in Veterinary Patients: A Review of the Literature.
4. Verganti et al. (2017): Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK. Journal of Small Animal Practice, 58(1):10–16.
5. Ottnod et al. (2013): A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. Veterinary and Comparative Oncology.
6. Boehringer Ingelheim Specialist Form: 2024 Oncept Order Form (ACVIM and ACVR restriction rules).
7. USDA APHIS Center for Veterinary Biologics: Canine Melanoma Vaccine, DNA, Product Code 9240.D0 Environmental Assessment.